Fibrosis risk assessment in patients younger than 35 years with fatty liver disease
In patients younger than 35 years, the FIB-4 index has low accuracy for fibrosis risk stratification, so secondary fibrosis assessment should be used rather than relying on FIB-4 alone. [1] Secondary assessment should be considered in those younger than 35 years with increased metabolic risk or elevated liver chemistries. [1]
Medication Selection Algorithm
Not applicable to fibrosis risk assessment. [1]
Fibrosis risk assessment algorithm
Sequential noninvasive assessment is recommended when serum fibrosis scores have limitations. [1] For age younger than 35 years:
- Serum fibrosis scoring with FIB-4 should not be used as the sole decision tool because accuracy is reduced in this age group. [1]
- Secondary assessment should be performed when metabolic risk is increased or liver chemistries are elevated. [1]
- Secondary assessment should preferentially use vibration-controlled transient elastography (VCTE) or Enhanced Liver Fibrosis (ELF) testing initially. [1]
- Liver stiffness measurement (LSM) and ELF thresholds can be used to exclude advanced fibrosis based on noninvasive cutoffs. [2]
Monotherapy versus combination therapy approach
FIB-4 should not be used as monotherapy for fibrosis staging in patients younger than 35 years because the score is not accurate in this age group. [1] Combination noninvasive evaluation may be used when secondary tests are required after serum scoring is limited by age. [1]
Key evidence supporting this recommendation
AASLD practice guidance states that FIB-4 has low accuracy in individuals under age 35 years, prompting secondary assessment in this group when clinical risk is elevated. [1] EASL noninvasive testing guidance provides rule-out thresholds for advanced fibrosis using LSM and ELF. [2]
Initiation thresholds and referral triggers
Secondary assessment is recommended in patients younger than 35 years with either:
- Increased metabolic risk. [1]
- Elevated liver chemistries. [1] Rule-out thresholds for advanced fibrosis using secondary tests are available for noninvasive decision-making. [2]
Targets or goals of therapy
The goal of fibrosis risk assessment is exclusion of advanced fibrosis using noninvasive cutoffs when secondary tests are performed. [2]
Common pitfalls to avoid
FIB-4-based triage should not be used as the only fibrosis risk assessment strategy in patients younger than 35 years because diagnostic accuracy is reduced. [1]
Noninvasive targets for excluding advanced fibrosis
Advanced fibrosis risk can be excluded using noninvasive cutoffs, including:
- LSM < 8 kPa. [2]
- ELF score < 9.8. [2]
- FIB-4 < 1.3 or NAFLD fibrosis score (NFS) < −1.455 can exclude advanced NAFLD fibrosis in general populations, but age limitations apply in patients younger than 35 years. [1,2]
Next-step escalation after inconclusive noninvasive assessment
If noninvasive testing suggests advanced fibrosis or cirrhosis, management pathways based on advanced fibrosis/cirrhosis should be used without waiting for liver biopsy in appropriate clinical contexts. [1]